Boston Scientific has received FDA approval for a new drug-eluting stent (DES). The TAXUS Express Atom Stent is the only DES approved by the FDA for use in vessels as small as 2.25 mm in diameter. Read more here.
Eight large medical device and pharmaceutical companies are collaborating on a $100MM clinical trial to assess late-stent thrombosis. The eight companies include the four big players in DES (Abbott, Cordis, Boston Scientific, and Medtronic) and four large pharma companies (Bristol-Myers Squibb, Sanofi Aventis, Eli Lilly, and Daiichi Sankyo). Read more from the Wall Street Journal.
Medtronic wins a lawsuit against Abbott for its new Endeavor stent. The Endeavor received clearance from FDA in February 2008.
CeloNova Bioscience’s CANTANIA DES stent is “. . . highly lubricious and delivers low restenosis rates, excellent anti-thrombosis rates, and other clinical benefits that approach or, in some cases, may exceed those of DES, while addressing some of the significant ongoing concerns with current DES technology such as product cost, risk for thrombosis, and serious challenges associated with costly long-term dual anti-platelet therapy following treatment.” This product is currently available in Europe. Read more here.
This article from MD&DI discusses a number of cardiovascular technologies and products, including stents.
